Education
About Us
Working with TipRanks
Follow Us
CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
RESEARCH TOOLSreports
Total Valuation
CytoMed Therapeutics Limited has a market cap or net worth of $26.10M. The enterprise value is $33.62M.
Market Cap$26.10M
Enterprise Value$33.62M
Share Statistics
CytoMed Therapeutics Limited has 12,550,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,550,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CytoMed Therapeutics Limited’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -38.58%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-38.58%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee1.21K
Profits Per Employee-43.79K
Employee Count43
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CytoMed Therapeutics Limited is -20.83. CytoMed Therapeutics Limited’s PEG ratio is -0.35.
PE Ratio-20.83
PS Ratio0.00
PB Ratio72.61
Price to Fair Value5.97
Price to FCF-22.76
Price to Operating Cash Flow-30.48
PEG Ratio-0.35
Income Statement
In the last 12 months, CytoMed Therapeutics Limited had revenue of 52.01K and earned -1.88M in profits. Earnings per share was -0.16.
Revenue52.01K
Gross Profit-515.82K
Operating Income-2.63M
Pretax Income-1.90M
Net Income-1.88M
EBITDA-1.79M
Earnings Per Share (EPS)-0.16
Cash Flow
In the last 12 months, operating cash flow was -1.71M and capital expenditures -1.06M, giving a free cash flow of -2.76M billion.
Operating Cash Flow-1.71M
Free Cash Flow-2.76M
Free Cash Flow per Share-0.22
Dividends & Yields
CytoMed Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.40
52-Week Price Change2.46%
50-Day Moving Average2.28
200-Day Moving Average2.34
Relative Strength Index (RSI)43.86
Average Volume (3m)7.64K
Important Dates
CytoMed Therapeutics Limited upcoming earnings date is Nov 14, 2025, TBA Not Confirmed.
Last Earnings DateApr 28, 2025
Next Earnings DateNov 14, 2025
Ex-Dividend Date―
Financial Position
CytoMed Therapeutics Limited as a current ratio of 7.25, with Debt / Equity ratio of 718.81%
Current Ratio7.25
Quick Ratio7.25
Debt to Market Cap0.01
Net Debt to EBITDA1.66
Interest Coverage Ratio-172.79
Taxes
In the past 12 months, CytoMed Therapeutics Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CytoMed Therapeutics Limited EV to EBITDA ratio is -20.25, with an EV/FCF ratio of -13.22.
EV to Sales697.16
EV to EBITDA-20.25
EV to Free Cash Flow-13.22
EV to Operating Cash Flow-21.39
Balance Sheet
CytoMed Therapeutics Limited has $3.64M in cash and marketable securities with $463.25K in debt, giving a net cash position of -$3.18M billion.
Cash & Marketable Securities$3.64M
Total Debt$463.25K
Net Cash-$3.18M
Net Cash Per Share-$0.25
Tangible Book Value Per Share$0.57
Margins
Gross margin is 97.60%, with operating margin of -5049.84%, and net profit margin of -3621.15%.
Gross Margin97.60%
Operating Margin-5049.84%
Pretax Margin-3648.38%
Net Profit Margin-3621.15%
EBITDA Margin-3443.05%
EBIT Margin-3619.16%
Analyst Forecast
The average price target for CytoMed Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast38.80%